Protocol Ledger

NCT03806127 · Phase II · COMPLETED

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Interventional Phase II clinical trial protocol NCT03806127 sponsored by Urovant Sciences in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-31 Enrollment: 222 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03806127
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)222 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03806127
Protocol FieldVerified Registry Value
NCT IdentifierNCT03806127
Consolidated Lead SponsorUrovant Sciences
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment222 participants (ACTUAL)
Registered Start Date2018-12-31
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI